2021
DOI: 10.3390/ph14010040
|View full text |Cite
|
Sign up to set email alerts
|

Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf

Abstract: The impressive improvement of overall survival in multiple myeloma (MM) patients in the last years has been mostly related to the availability of new classes of drugs with different mechanisms of action, including proteasome inhibitors (PI), immunomodulating agents (IMiDs), and monoclonal antibodies. However, even with this increased potence of fire, MM still remains an incurable condition, due to clonal selection and evolution of neoplastic clone. This concept underlines the importance of immunotherapy as one… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
6
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 8 publications
(6 citation statements)
references
References 73 publications
(57 reference statements)
0
6
0
Order By: Relevance
“…Other BCMA-targeting ADCs include AMG-224, CC-99712, SG1-auristatin, MEDI228, and HDP-101, as summarized in very recent comprehensive reviews (172,(185)(186)(187).…”
Section: How To Target Bcma In Multiple Myeloma: the Antibodies Drug Conjugatesmentioning
confidence: 99%
“…Other BCMA-targeting ADCs include AMG-224, CC-99712, SG1-auristatin, MEDI228, and HDP-101, as summarized in very recent comprehensive reviews (172,(185)(186)(187).…”
Section: How To Target Bcma In Multiple Myeloma: the Antibodies Drug Conjugatesmentioning
confidence: 99%
“…5 Several innovative targeted therapies, such as monoclonal antibodies, CAR-Tcell therapy, antibody-drug conjugates and bispecific antibodies, have made rapid progress in MM. [6][7][8] Furthermore, with the continuous improvement of new technologies and treatment methods, research on biomarkers for MM is steadily developing and is continuously being applied to risk stratification, prognosis assessment and the small-molecule inhibitor selection of subsequent treatment for MM patients. 9 However, the recurrence of MM is still common, and therefore, deeper research into the molecular mechanisms underlying the occurrence and development of MM is needed.…”
Section: Introductionmentioning
confidence: 99%
“…Despite some progress in treatment strategies for MM, including the use of novel drugs such as proteasome inhibitors, immunomodulatory agents and monoclonal antibodies for younger patients, as well as autologous stem cell transplantation for eligible individuals, MM still remains a challenge 5 . Several innovative targeted therapies, such as monoclonal antibodies, CAR‐Tcell therapy, antibody–drug conjugates and bispecific antibodies, have made rapid progress in MM 6–8 . Furthermore, with the continuous improvement of new technologies and treatment methods, research on biomarkers for MM is steadily developing and is continuously being applied to risk stratification, prognosis assessment and the small‐molecule inhibitor selection of subsequent treatment for MM patients 9 .…”
Section: Introductionmentioning
confidence: 99%
“… 3 , 5 T-cell bispecific antibodies in development include CC-93269 (BCMA-CD3 trivalent), teclistamab (BCMA-CD3) and talquetamab (GPCR5D-CD3). 6 Despite therapeutic advances, MM remains incurable for the majority of patients due to the selection of unresponsive, drug-resistant tumor cells, making relapse imminent.…”
Section: Introductionmentioning
confidence: 99%